While mice treated with anti-CTLA4 alone did not exhibit significantly decreased tumor growth compared to the control group, the combination of EC5026 and anti-CTLA4 treatment significantly suppressed MB49 bladder cancer tumor growth compared to control (Fig. 4B). Here, CTLA4 is linked to urinary bladder carcinoma.